Clarissa Willett | VP, IR |
David King | Chairman, CEO & President |
Glenn Eisenberg | CFO & EVP |
John Ratliff | CEO, Covance Drug Development |
Lisa Gill | JPMorgan |
Kevin Caliendo | UBS |
Jack Meehan | Barclays |
Ross Muken | Evercore ISI |
Dan Leonard | Deutsche Bank |
Erin Wright | Credit Suisse |
Ricky Goldwasser | Morgan Stanley |
Stephen Baxter | Wolfe Research |
Patrick Donnelly | Goldman Sachs |
Bill Quirk | Piper Jaffray |
Brian Tanquilut | Jefferies |
Donald Hooker | KeyBanc |
Kevin Ellich | Craig-Hallum |
Ralph Giacobbe | Citi |
Good day | ladies and gentlemen - and welcome to the First Quarter 2019 LabCorp Holdings Earnings Conference Call. At this time - all participants are in a listen-only mode. Later - we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder - this call is being recorded. |
I would now like to introduce your host for today's conference | Clarissa Willett - Vice President of Investor Relations. Please go ahead. |
Good morning and welcome to LabCorp's first quarter 2019 conference call.
As detailed in today's press release, there will be a replay of this conference call available via telephone and Internet. With me today are Dave King, Chairman and Chief Executive Officer; Glenn Eisenberg, Executive Vice President and Chief Financial Officer; and John Ratliff, CEO of Covance Drug Development. This morning, in the Investor Relations section of our website at www.labcorp.com. we posted both our press release and an investor relations presentation with additional information on our business and operations, which includes a reconciliation of the non-GAAP financial measures to the GAAP financial measures discussed during today's call.